Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

STAT3, the Challenge for Chemotherapeutic and Radiotherapeutic Efficacy
Ping-Lian Yang, Lu-Xin Liu, En‐Min Li, et al.
Cancers (2020) Vol. 12, Iss. 9, pp. 2459-2459
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

STAT3-EMT axis in tumors: Modulation of cancer metastasis, stemness and therapy response
Mehrdokht Sadrkhanloo, Maliheh Entezari, Sima Orouei, et al.
Pharmacological Research (2022) Vol. 182, pp. 106311-106311
Closed Access | Times Cited: 110
Sulconazole Induces PANoptosis by Triggering Oxidative Stress and Inhibiting Glycolysis to Increase Radiosensitivity in Esophageal Cancer
Lu-Xin Liu, Jing-Hua Heng, Dan-Xia Deng, et al.
Molecular & Cellular Proteomics (2023) Vol. 22, Iss. 6, pp. 100551-100551
Open Access | Times Cited: 43
Transforming growth factor-beta (TGF-β) in prostate cancer: A dual function mediator?
Sepideh Mirzaei, Mahshid Deldar Abad Paskeh, Yalda Saghari, et al.
International Journal of Biological Macromolecules (2022) Vol. 206, pp. 435-452
Closed Access | Times Cited: 44
Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases
Peter C. Taylor, Ernest Choy, Xenofon Baraliakos, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 2, pp. 298-308
Open Access | Times Cited: 32
DeepInsight-3D architecture for anti-cancer drug response prediction with deep-learning on multi-omics
Alok Sharma, Artem Lysenko, Keith A. Boroevich, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 28
Structure, function, signaling pathways and clinical therapeutics: The translational potential of STAT3 as a target for cancer therapy
Dandan Shi, Jiejing Tao, Shuli Man, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 6, pp. 189207-189207
Closed Access | Times Cited: 6
Drugging the ‘undruggable’. Therapeutic targeting of protein–DNA interactions with the use of computer-aided drug discovery methods
Mariia Radaeva, Anh‐Tien Ton, Michael Hsing, et al.
Drug Discovery Today (2021) Vol. 26, Iss. 11, pp. 2660-2679
Open Access | Times Cited: 37
STAT3 regulates 5‐Fu resistance in human colorectal cancer cells by promoting Mcl‐1–dependent cytoprotective autophagy
Yuanyi Yue, Qiang Zhang, Xueqing Wang, et al.
Cancer Science (2023) Vol. 114, Iss. 6, pp. 2293-2305
Open Access | Times Cited: 13
It’s all downstream from here: RTK/Raf/MEK/ERK pathway resistance mechanisms in glioblastoma
Rebeca Yakubov, Ramneet Kaloti, Phooja Persaud, et al.
Journal of Neuro-Oncology (2025)
Open Access
STAT3 Signaling Pathway in Health and Disease
Md Abdus Samad, Iftikhar Ahmad, A. M. Mahedi Hasan, et al.
MedComm (2025) Vol. 6, Iss. 4
Open Access
Unveiling the Role of JAK2/STAT3 Signaling in Chemoresistance of Gynecological Cancers: From Mechanisms to Therapeutic Implications
Tianxiao Zhang, Chang Xiaohan
Critical Reviews in Oncology/Hematology (2025), pp. 104712-104712
Closed Access
Targeting STAT3 for Cancer Therapy: Focusing on Y705, S727, or Dual Inhibition?
Kyli Berkley, Julian Zalejski, Ashutosh Sharma
Cancers (2025) Vol. 17, Iss. 5, pp. 755-755
Open Access
Cardiac Glycoside Ouabain Exerts Anticancer Activity via Downregulation of STAT3
Jie Du, Lijun Jiang, Fuqiang Chen, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 26
Pharmacological Targeting of STING-Dependent IL-6 Production in Cancer Cells
Sumaiah S. Al-Asmari, Aleksandra Rajapakse, Tomalika R. Ullah, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 9
Open Access | Times Cited: 17
Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo
Peibin Yue, Yinsong Zhu, Christine Brotherton‐Pleiss, et al.
Cancer Letters (2022) Vol. 534, pp. 215613-215613
Open Access | Times Cited: 16
The Role of STATs in Ovarian Cancer: Exploring Their Potential for Therapy
David Standing, Emma Feess, Satvik Kodiyalam, et al.
Cancers (2023) Vol. 15, Iss. 9, pp. 2485-2485
Open Access | Times Cited: 10
Antibody–Drug Conjugate αEGFR-E-P125A Reduces Triple-negative Breast Cancer Vasculogenic Mimicry, Motility, and Metastasis through Inhibition of EGFR, Integrin, and FAK/STAT3 Signaling
Ankita P. Sankar, Hyun‐Mi Cho, Seung-Uon Shin, et al.
Cancer Research Communications (2024) Vol. 4, Iss. 3, pp. 738-756
Open Access | Times Cited: 3
Inhibition of STAT3: A promising approach to enhancing the efficacy of chemotherapy in medulloblastoma
Sachindra Kumar, Dube Aakash Arwind, Harish Kumar B, et al.
Translational Oncology (2024) Vol. 46, pp. 102023-102023
Open Access | Times Cited: 3
Co-targeting JAK1/STAT6/GAS6/TAM signaling improves chemotherapy efficacy in Ewing sarcoma
Le Yu, Yu Deng, Xiaodong Wang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Characterization of EGFR-reprogrammable temozolomide-resistant cells in a model of glioblastoma
Lingli Gong, Ying Yin, Chen Cheng, et al.
Cell Death Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 14
Inactivation of EGFR/ERK/NF‐κB signalling associates with radiosensitizing effect of 18β‐glycyrrhetinic acid on progression of hepatocellular carcinoma
Yu‐Chang Liu, Cheng Hsun Lin, Kuan‐Tin Chen, et al.
Journal of Cellular and Molecular Medicine (2023) Vol. 27, Iss. 11, pp. 1539-1549
Open Access | Times Cited: 7
Feasibility of the inhibitor development for cancer: A systematic approach for drug design
Yu Jiang, Ling Liu, Yichao Geng, et al.
PLoS ONE (2024) Vol. 19, Iss. 8, pp. e0306632-e0306632
Open Access | Times Cited: 2
AKR1C1 interacts with STAT3 to increase intracellular glutathione and confers resistance to oxaliplatin in colorectal cancer
Zhiwen Fu, Tingting Wu, Chen Gao, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 12, pp. 5305-5320
Open Access | Times Cited: 2
Impact of Different JAK Inhibitors and Methotrexate on Lymphocyte Proliferation and DNA Damage
Annika Reddig, L D Voss, Karina Guttek, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 7, pp. 1431-1431
Open Access | Times Cited: 16
FIBP interacts with transcription factor STAT3 to induce EME1 expression and drive radioresistance in lung adenocarcinoma
Yunhong Xu, Jun Li, Kuikui Zhu, et al.
International Journal of Biological Sciences (2023) Vol. 19, Iss. 12, pp. 3816-3829
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top